Celcuity's Gedatolisib Hits Primary Endpoint in Phase 3 Trial, Expands Breast Cancer Indications
Event summary
- Celcuity's Phase 3 VIKTORIA-1 trial met primary endpoint, showing clinically meaningful improvement in progression-free survival for PIK3CA mutant cohort.
- Phase 3 VIKTORIA-2 trial expanded to include a second study evaluating gedatolisib as first-line treatment in endocrine-sensitive HR+/HER2- advanced breast cancer.
- First patent application submitted for subcutaneous formulation of gedatolisib.
- Net loss for Q1 2026 was $52.8 million, up from $37.0 million in Q1 2025.
The big picture
Celcuity's positive Phase 3 results position gedatolisib as a potential standard of care for advanced breast cancer, expanding its market reach. The company's strategic move to develop a subcutaneous formulation and its focus on first-line treatment indications reflect a broader industry trend toward more convenient and comprehensive cancer therapies. With significant financial investments in R&D and commercialization, Celcuity is betting on gedatolisib to drive long-term growth in the competitive oncology space.
What we're watching
- Regulatory Timeline
- Whether Celcuity can secure FDA approval for gedatolisib by the third quarter of 2026 as planned.
- Market Expansion
- The pace at which Celcuity can expand gedatolisib's indications to cover nearly all patients in the first-line setting.
- Financial Sustainability
- How Celcuity will manage increasing operating expenses and net losses while advancing multiple clinical trials.
Related topics